RAPID DETECTION OF PROGNOSTIC GENETIC-FACTORS IN NEUROBLASTOMA USING FLUORESCENCE IN-SITU HYBRIDIZATION ON TUMOR IMPRINTS AND BONE-MARROW SMEARS

被引:43
作者
TAYLOR, CPF
MCGUCKIN, AG
BOWN, NP
REID, MM
MALCOLM, AJ
PEARSON, ADJ
SHEER, D
机构
[1] UNIV NEWCASTLE UPON TYNE,ROYAL VICTORIA INFIRM,DIV PATHOL,NEWCASTLE TYNE NE1 4LP,ENGLAND
[2] UNIV NEWCASTLE UPON TYNE,ROYAL VICTORIA INFIRM,DIV HUMAN GENET,NEWCASTLE TYNE NE1 4LP,ENGLAND
[3] UNIV NEWCASTLE UPON TYNE,ROYAL VICTORIA INFIRM,DEPT HAEMATOL,NEWCASTLE TYNE NE1 4LP,ENGLAND
[4] UNIV NEWCASTLE UPON TYNE,ROYAL VICTORIA INFIRM,DEPT HISTOPATHOL,NEWCASTLE TYNE NE1 4LP,ENGLAND
[5] UNIV NEWCASTLE UPON TYNE,ROYAL VICTORIA INFIRM,DEPT CHILD HLTH,NEWCASTLE TYNE NE1 4LP,ENGLAND
关键词
D O I
10.1038/bjc.1994.81
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A number of biological Factors have been identified which correlate with prognosis in neuroblastoma. Among these are genetic aberrations, including ploidy, deletions of chromosome 1p and N-myc amplification. Conventional methods of detecting these changes, such as tissue culture for karyotyping and Southern blotting, are time-consuming and yield interpretable results in only a small proportion of cases. We have developed interphase fluorescence in situ hybridisation for use on tumour imprints and bone marrow smears, allowing rapid visualisation of the relevant genetic changes. Valuable prognostic information is therefore available in a few days: the results in our cases were later confirmed by conventional methods. In the foreseeable future it will be possible to define distinct prognostic categories on the basis both of this genetic information and other parameters, and separate therapeutic strategies may then be employed for the different patient groups.
引用
收藏
页码:445 / 451
页数:7
相关论文
共 27 条
[1]  
BOURHIS J, 1991, CANCER RES, V51, P33
[2]   REVISIONS OF THE INTERNATIONAL CRITERIA FOR NEUROBLASTOMA DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT [J].
BRODEUR, GM ;
PRITCHARD, J ;
BERTHOLD, F ;
CARLSEN, NLT ;
CASTEL, V ;
CASTLEBERRY, RP ;
DEBERNARDI, B ;
EVANS, AE ;
FAVROT, M ;
HEDBORG, F ;
KANEKO, M ;
KEMSHEAD, J ;
LAMPERT, F ;
LEE, REJ ;
LOOK, AT ;
PEARSON, ADJ ;
PHILIP, T ;
ROALD, B ;
SAWADA, T ;
SEEGER, RC ;
TSUCHIDA, Y ;
VOUTE, PA .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) :1466-1477
[3]   MOLECULAR-BIOLOGY AND GENETICS OF HUMAN NEURO-BLASTOMA [J].
BRODEUR, GM ;
FONG, CT .
CANCER GENETICS AND CYTOGENETICS, 1989, 41 (02) :153-174
[4]   INTERNATIONAL CRITERIA FOR DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT IN PATIENTS WITH NEURO-BLASTOMA [J].
BRODEUR, GM ;
SEEGER, RC ;
BARRETT, A ;
BERTHOLD, F ;
CASTLEBERRY, RP ;
DANGIO, G ;
DEBERNARDI, B ;
EVANS, AE ;
FAVROT, M ;
FREEMAN, AI ;
HAASE, G ;
HARTMANN, O ;
HAYES, FA ;
HELSON, L ;
KEMSHEAD, J ;
LAMPERT, F ;
NINANE, J ;
OHKAWA, H ;
PHILIP, T ;
PINKERTON, CR ;
PRITCHARD, J ;
SAWADA, T ;
SIEGEL, S ;
SMITH, EI ;
TSUCHIDA, Y ;
VOUTE, PA .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (12) :1874-1881
[6]   TUMOR KARYOTYPE DISCRIMINATES BETWEEN GOOD AND BAD PROGNOSTIC OUTCOME IN NEURO-BLASTOMA [J].
CHRISTIANSEN, H ;
LAMPERT, F .
BRITISH JOURNAL OF CANCER, 1988, 57 (01) :121-126
[7]   CLINICAL IMPACT OF CHROMOSOME-I ABERRATIONS IN NEUROBLASTOMA - A METAPHASE AND INTERPHASE CYTOGENETIC STUDY [J].
CHRISTIANSEN, H ;
SCHESTAG, J ;
CHRISTIANSEN, NM ;
GRZESCHIK, KH ;
LAMPERT, F .
GENES CHROMOSOMES & CANCER, 1992, 5 (02) :141-149
[8]   CLONING OF HUMAN SATELLITE-III DNA - DIFFERENT COMPONENTS ARE ON DIFFERENT CHROMOSOMES [J].
COOKE, HJ ;
HINDLEY, J .
NUCLEIC ACIDS RESEARCH, 1979, 6 (10) :3177-3197
[9]   CYTOGENETICS AND MOLECULAR-BIOLOGY OF SMALL ROUND-CELL TUMORS AND RELATED NEOPLASMS - CURRENT STATUS [J].
DONNER, LR .
CANCER GENETICS AND CYTOGENETICS, 1991, 54 (01) :1-10
[10]  
EVANS AE, 1987, CANCER, V59, P1853, DOI 10.1002/1097-0142(19870601)59:11<1853::AID-CNCR2820591102>3.0.CO